Glenmark Pharmaceuticals Ltd. (GLENMARK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 780863, "name": "Glenmark Pharma", "stock_name": "Glenmark Pharma", "full_name": "Glenmark Pharmaceuticals Ltd.", "name_url": "stocks-analysis/glenmark-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "2,271.55", "chg": 61.7, "chgp": "2.79%", "dir": 1, "prev_price": "2,209.85", "mcapval": "64,103.32 Cr", "mcap": "Mid Cap", "scripcode": 532296, "symbol": "GLENMARK", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE935A01035", "curr_date": "Jul 06, 02:20 PM", "curr_time": "14:21 PM", "last_traded_at": "Jul 06, 02:20 PM IST", "bse_nse_vol": "4.67 lacs", "exc_status": "Active", "traded_date": "Jul 06, 2026", "traded_date_str": "2026 07 06", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score", "mojoone": { "text": "Part of MojoOne Strategy", "type": "SM", "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month", "ismore": 0, "all_data": [], "is_blur": 1, "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies" } }, "news": { "results": [ { "title": "Glenmark Pharmaceuticals Ltd. Exhibits Mildly Bullish Momentum Amid Mixed Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-exhibits-mildly-bullish-momentum-amid-mixed-technical-signals-4089979", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_technicaldot_4089979.png", "date": "2026-07-06 08:02:34", "description": "Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock has demonstrated resilience with a 0.68% gain on 6 July 2026, closing at ₹2,209.85." }, { "title": "Glenmark Pharmaceuticals Gains 1.08%: Mixed Technical Signals Amid Strong Fundamentals", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-108-mixed-technical-signals-amid-strong-fundamentals-4088868", "imagepath": "", "date": "2026-07-04 15:07:10", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>29 Jun:</strong> Sharp open interest surge amid bullish market positioning</p>\n <p><strong>2 Jul:</strong> Mojo Grade downgraded to Hold reflecting technical setbacks</p>\n <p><strong>2 Jul:</strong> Technical momentum shifts to sideways amid mixed signals</p>\n <p><strong>3 Jul:</strong> Week closes at Rs.2,209.85 (+1.08%) vs Sensex +1.31%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,186.20</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class..." }, { "title": "Glenmark Pharmaceuticals Downgraded to Hold Amid Technical Setbacks Despite Strong Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-downgraded-to-hold-amid-technical-setbacks-despite-strong-fundamentals-4084284", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_mojoScore_4084284.png", "date": "2026-07-02 08:42:48", "description": "Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 1 July 2026. This adjustment reflects a nuanced reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite strong financial performance and attractive long-term returns, evolving technical indicators and valuation metrics have prompted a more cautious stance among analysts." }, { "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4083901", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_technicaldot_4083901.png", "date": "2026-07-02 08:06:26", "description": "Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment as the stock price dips 2.14% to ₹2,157.70 on 2 Jul 2026." }, { "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Positioning", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-bullish-market-positioning-4077429", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_oi_spurts_by_underlying_4077429.png", "date": "2026-06-29 15:00:36", "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector peers and the broader Sensex, reflecting renewed investor interest amid evolving market dynamics." }, { "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-bullish-derivatives-activity-4077319", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_oi_spurts_by_underlying_4077319.png", "date": "2026-06-29 14:00:32", "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.24% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a moderate 1.62% gain in the stock price, the surge in open interest alongside volume patterns suggests evolving directional bets in this mid-cap pharmaceutical player." }, { "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-market-signals-4077229", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_oi_spurts_by_underlying_4077229.png", "date": "2026-06-29 13:00:25", "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 11.63% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 1.24% gain in the stock price, the surge in open interest coupled with volume patterns suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector." }, { "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-4073608", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_oi_spurts_by_underlying_4073608.png", "date": "2026-06-25 15:00:52", "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, with an 18.7% increase signalling heightened market activity. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor positioning and market sentiment in the Pharmaceuticals & Biotechnology space." }, { "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action", "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-4073458", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GlenmarkPharmac_oi_spurts_by_underlying_4073458.png", "date": "2026-06-25 14:00:43", "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.2% increase in open interest in its derivatives segment, signalling heightened market activity despite a modest decline in its share price. This surge in open interest, coupled with shifting volume patterns and subdued investor participation, offers a nuanced view of market positioning and potential directional bets on the mid-cap pharmaceutical stock." } ], "total": 576, "sid": "780863", "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "02-Jul-2026", "details": "Glenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer", "source": "BSE" }, { "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015", "datetime": "30-Jun-2026", "details": "US FDA inspection at Companys manufacturing facility in Goa India", "source": "BSE" }, { "caption": "Closure of Trading Window", "datetime": "25-Jun-2026", "details": "Intimation of Closure of Trading Window", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25", "dt": "2025-10-03", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07", "dt": "2007-09-10", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

29 Jun: Sharp open interest surge amid bullish market positioning

2 Jul: Mojo Grade downgraded to Hold reflecting technical setbacks

2 Jul: Technical momentum shifts to sideways amid mixed signals

3 Jul: Week closes at Rs.2,209.85 (+1.08%) vs Sensex +1.31%

Week Open

Rs.2,186.20

Week Close

Read full news article

Glenmark Pharmaceuticals Downgraded to Hold Amid Technical Setbacks Despite Strong Fundamentals

2026-07-02 08:42:48

Glenmark Pharmaceuticals Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 1 July 2026. This adjustment reflects a nuanced reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite strong financial performance and attractive long-term returns, evolving technical indicators and valuation metrics have prompted a more cautious stance among analysts.

Read full news article

Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-07-02 08:06:26

Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This change is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment as the stock price dips 2.14% to ₹2,157.70 on 2 Jul 2026.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Positioning

2026-06-29 15:00:36

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector peers and the broader Sensex, reflecting renewed investor interest amid evolving market dynamics.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity

2026-06-29 14:00:32

Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.24% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a moderate 1.62% gain in the stock price, the surge in open interest alongside volume patterns suggests evolving directional bets in this mid-cap pharmaceutical player.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals

2026-06-29 13:00:25

Glenmark Pharmaceuticals Ltd. has witnessed a notable 11.63% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest 1.24% gain in the stock price, the surge in open interest coupled with volume patterns suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-06-25 15:00:52

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, with an 18.7% increase signalling heightened market activity. Despite this, the stock underperformed its sector and broader indices, reflecting a complex interplay of investor positioning and market sentiment in the Pharmaceuticals & Biotechnology space.

Read full news article

Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-06-25 14:00:43

Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.2% increase in open interest in its derivatives segment, signalling heightened market activity despite a modest decline in its share price. This surge in open interest, coupled with shifting volume patterns and subdued investor participation, offers a nuanced view of market positioning and potential directional bets on the mid-cap pharmaceutical stock.

Read full news article